HOME > BUSINESS > Syngene International buys systems biology and pharma services assets of Strand Life Sciences

Syngene International buys systems biology and pharma services assets of Strand Life Sciences

syngeneSyngene International Ltd., Asia’s largest contract research organization, said it has purchased assets of Strand Life Sciences related to systems biology, Heptox and Pharma Bioinformatics services.

Financial details of the deal were not disclosed.

The acquisition includes target dossier business and rights to NGS data analytics and Sarchitect platforms, supported by a strong scientific team.

Syngene International Limited, is one of Asia’s largest contract research organizations. It provides discovery and developmental services for new molecular entities across multiple platforms including small molecules, large molecules, antibody-drug conjugates, etc.

In FY2016, Syngene serviced 256 clients including 8 of the top 10 global pharma companies.

Strand Life Sciences is a global genomic profiling company and offers medicine diagnostics, aimed at empowering cancer care and genetic testing for inherited diseases.

“Given the vast volumes of genetic material sequence data that is being generated globally, there is an increasing focus on biological information management and data analytics in drug discovery and development,” said Jonathan Hunt, Chief Executive Officer, Syngene International.

This deal gives Syngene access to Strand’s patented Virtual Liver model and the NGS analytics platform. The Virtual Liver model is able to predict the toxic effect of different drugs or chemicals on the liver (both rat and human) using information from laboratory- based experiments prior to actual testing on live animals or humans. Strand NGS is an integrated platform that provides analysis, management and visualization tools for next-generation sequencing data.

“Syngene is constantly looking for new opportunities to expand its service offerings into areas such as NGS, translational R&D, predictive toxicology and pre-emptive target validation services, all of which require strong bioinformatics capabilities. We believe Strand’s bioinformatics platforms not only complement our existing integrated service platforms but will also meet our customers growing needs for bioinformatics and data analytic support,” he further said.

Bioinformatics is a rapidly emerging area that promises tremendous growth potential.

Companies involved in pharmaceutical, cosmetics, FMCG and agro-biotech R&D have strong focus on genomics, and need sound bioinformatics applications and platforms for developing better therapeutics and products.

According to transparency market research, the global bioinformatics market was estimated at $2.3 billion in 2012 and is forecasted to reach a market size of $9.1 billion in 2018, at a CAGR of 25.4%.

“The deal with Syngene gives Syngene access to technologies from Strand to form part of its integrated discovery service offerings. This transaction is also a key step for Strand to focus its energies on personalized medicine through clinical applications of all its genomics technologies,” added Chairman and Managing Director of Strand Life Sciences, Dr. Vijay Chandru.

Strand works with physicians and hospitals to enable faster clinical decision support for accurate molecular diagnosis, prognosis, therapy recommendations, and clinical trials.

Follow ULTRA.news
Lupin gets FDA nod for generic cholesterol drug Pharmaceuticals company Lupin said it received a 505 (b)(2) NDA approval for its Nikita"M (Pitavastatin) Tablets 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (FDA).A 505(b)(2) approval refers to one given by relying on studies already performed on a...
Strides Shasun to launch allergy drug in the US Pharma company Strides Shasun said it had received approval allergy drug Cetirizine Hydrochloride in the US."The US market for Cetirizine Hydrochloride Capsules (Softgel) is approximately USD 60 mln, with only one other generic player," the company said."The product is re...
Reliance Capital receives Rs 378 cr from Nippon Life for AMC stake Anil Ambani Group's Reliance Capital said it received Rs. 378 crore from Nippon Life Insurance, one of the largest life insurers in the world, after the foreign company increased its stake in Reliance Nippon Life Asset Management Limited to 49%.The original agreement to incre...
Glenmark Pharma gets UK OTC approval for anti-malarial medicine Glenmark Pharmaceuticals said it received approval from UK authorities for to sell its Maloff Protect anti-malarial medication without prescription.It contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK.The Me...
Sun Pharma selects Samsung to manufacture psoriasis drug Sun Pharma said it has inked a long-term agreement with Samsung BioLogics under which the Korean company will manufacture Tildrakizumab, a potential treatment for plaque psoriasis, for the Indian company.Plaque psoriasis is an autoimmune condition which results in patches of ...
Bajaj Auto, KTM decide to invest into Husqvarna motorcycle brand Bajaj Auto said it agreed with its Austrian associate KTM to expand the brand sales and shift some of the production of Husqvarna motorcycles to Bajaj's factory in Chakan, Maharashtra.The brand Husqvarna, founded in 1903 in Italy, used to be owned by BMW at one time. It was b...
Strides Shasun gets USFDA nod for nausea drug Pharmaceutical company Strides Shasun said it received approval from the United States Food & Drug Administration to sell nausea drug Promethazine Hydrochloride in the country.The US market for Promethazine Hydrochloride tablets is approximately USD 17 Million.It will be ...
Unichem Labs says USFDA completes inspection of Goa facility Unichem Laboratories said the US FDA has completed its inspection of the company's formulations manufacturing facility in Goa.Unichem Labs' formulations plant in GoaThe facility has received an Establishment Inspection Report, the company added."This receipt indica...
Zydus Cadila gets approval for obesity drug in USA Zydus Cadila said it received the final approval from the US FDA to market obesity drug Phentermine Hydrochloride.The drug will be marketed in the form of orally disintegrating tablets in strengths of 15 mg, 30 mg, and 37.5 mg.The drug is used to treat obesity in people w...
Zydus Cadila gets nod to sell ADHD drug in USA Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals received final approval from the US Food and Drug Administration to sell generic drug Dextroamphetamine Sulfate.Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyp...
News Corp buys Bangalore-based media software firm GyanMatrix Rupert Murdoch's News Corp announced yet another acquisition in India with the agreement to purchase Bangalore-based GyanMatrix Services Private Limited.P Hariharan, founder GyanMatrixThe company, which provides software solutions for media and publishing companies, will...
HPCL appoints bankers for Rs 6,000 cr FCCB issue Hindustan Petroleum Corp Ltd said it had appointed banking intermediaries for organizing investor meetings in the run up to raising Rs 6,000 cr ($930 mln) by selling foreign-currency denominated bonds.The bonds will be non-convertible, and will be issued if the meetings disco...
Zydus Cadila gets USFDA nod for Hepatitis B drug Zydus Cadila has received the final approval from the the US Food and Drug Administration to market Hepatitis B drug Entecavir.The drug has sales of $166.3 million in the US, and will be sold in 0.5 mg and 1 mg dosage.It will be produced at the group's formulations manufa...
Glenmark gets USFDA approval for generic joint-pain drug in US Glenmark Pharmaceuticals said it received final approval from the United States Food & Drug Administration for marketing a generic version of joint-pain drug Indocin of Iroko Pharmaceuticals.The drug has annual sales of approximately $6.3 million.With this, Glenmark’s ...
Lupin launches skin ointment in the US Pharma Major Lupin said it launched Desoximetasone cream for treating skin problems in the US market.The company had received approvals from the US Food and Drug Administration earlier.The drug is the generic equivalent of Tarot Pharma's Topicort, which had US sales of $...
Anil Ambani Group ties up with Thales for Rafale contracts Reliance Defence, the defence manufacturing arm of the Anil Ambani group, said it will form a joint venture in India with global defence manufacturer Thales to carry out some contracts related to the Rafale jet deal.The Indian company will hold 51% of the equity while the fo...
Axis Bank confirms exiting POS maker Mswipe Axis Bank confirmed it had sold its 8% share in new-generation card-swiping-machine company Mswipe Technologies.In a regulatory filing, the private sector bank said it sold its 8% stake for Rs 80.94 cr, or Rs 4,249 per share.Mswipe is one of the new generation, low-cost ...
Alembic Pharma to launch generic version of AstraZeneca heart drug in USA Alembic Pharmaceuticals said it received approval from the US Food & Drug Administration for selling a generic equivalent of AstraZeneca's heart drug Atacand.Approval was granted for the sale of candesantan cilexetil in the dosage of 32 mg.Candesartan cilexetil is used ...
Glenmark Pharma buy rights to cancer drug from US firm Glenmark Pharmaceuticals said it entered into a licensing agreement with Boston-based biopharmaceutical company APC Therapeutics Inc for exclusive rights for a cancer drug.The agreement covers a small molecule based on Antigen Presenting Cell (APC) biology, the Indian compa...
Zydus Cadila gets USFDA approval for generic version of popular migraine drug Zydus Cadila said it received final approval from the US Food and Drug Administration to market migraine drug Eletriptan Hydrobromide in the US.The drug is currently marketed and manufactured by Pfizer Inc and sold in the US and Canada under the brand name Relpax.The two...
Lupin launches generic antidepressant in the US India's second biggest pharmaceutical company Lupin said it has launched the generic version of Valeant's Wellbutrin antidepressant tablet Wellbutrin XL in the US.Wellbutrin XL tablet has yearly US sales of USD 758 million or about Rs 5,000 cr.It is used for the treatment...
Aurobindo Pharma launches kidney drug in the US Aurobindo Pharma said it received final approval from the US Food & Drug Administration to manufacture generic version of kidney drug Renvela from Genzyme.Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm is being launched immediately, the company said.The drug had ...
Lupin gets USFDA approval for pain relief drug Pharma Major Lupin said received final approval for launching a generic version of Mallinckrodt Inc.'s Roxicodone Tablets in the United States.The drug is used for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are...
Suven Life Sciences gets US, Australia patent for CNS molecule Suven Life Sciences Ltd said it got a patent from Australia and another from the US for a new molecule used for treating disorders associated with Neurodegenerative diseases.The 'new chemical entity' patent no 2014358652 from Australia is valid through 2032, while that from ...
Unichem Labs Ghaziabad plant inspected by USFDA Generic drug manufacturer Unichem Laboratories said its formulations manufacturing facility at Ghaziabad has successfully exited an inspection by the US Food and Drug Administration.Inside a Unichem plantIt received an Establishment Inspection Report (EIR) from the USFDA...